|
Watson, Actavis Merger Again Delayed by FTC Request for More Info
The FTC again is asking for more information from Watson Pharmaceuticals on its proposed $5.6 billion merger with Actavis, delaying its attempt to become the world’s third largest generic-drug company.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives